Table 3.
Classification of small molecule target therapy (‐ibs), intracellular target, and side effects
| Small molecule | End with name | Target | Target action | Side effect |
|---|---|---|---|---|
| Tyrosine kinase inhibitors | ‐tinib over 50 FDA approved | EGFR, VEGFR, PDGFR, FGFR, SCGFR, ALK, ERBB2, ITK, LCK, BTK, CDK | Inhibit cell function, growth factors, proliferation, angiogenesis | High blood pressure, bleeding, thrombosis, periorbital edema, cardiomyopathy |
| Proteasome inhibitors |
‐zomib Bortezomib (Velada) Carfilzomib (Kyprolis) Ixazomib (Ninlaro) |
Proteasome | Apoptosis‐cell death | Pancytopenia, peripheral neuropathy, diarrhea |
| Cyclin‐dependent inhibitors (CDK) |
‐ciclib Abemaciclib (Verzenio) Palbociclib (Ibrance) Ribociclib (Kisqali) |
CDK4/6‐HER2 | DNA synthesis‐cell death | Bone marrow suppression |
| Poly‐ADP‐ribosome polymerase inhibitors (PARP) |
‐parib Olaparib (Lynparza) Niraparib (Zejula) Rucaparib (Rubraca) Talazoparib (Talzenna) |
PARP‐BRACA1, BRACA2 | Inhibits DNA repair‐cell death | Bone marrow suppression, MDS, AML, HTN, hypertensive crisis |
EGFR Epidermal growth factor receptor, VEGFR Vasoendothelial growth factor receptor, PDGFR Platelet‐derived growth factor receptor, FGFR Fibroblast growth factor, SCGFR Stem cell growth factor, ALK Anaplastic lymphoma kinase, ERBB2 Breast cancer, ITK Interleukin‐2 receptor, LCK Leukocyte-specific protein kinase, BTK Bruton‐B-cell‐specific kinase, CDK Cyclic-dependent kinase, HER2 Breast cancer receptor, BRACA1, BRACA2 Breast cancer gene, MDS Myelodysplastic syndrome, AML Acute myeloid leukemia, HTN Hypertension